RadOnc Smart Review

Episode 5: Adjuvant Therapy, Active Surveillance, and Advanced Esophageal Cancer. A good response to treatment can lead to very different next steps in esophageal cancer. In this episode, we distinguish adjuvant therapy after resection, active surveillance after a carefully assessed clinical response, and treatment of advanced disease. We review CheckMate 577, SANO, biomarker interpretation, and s...

Episode 4: Definitive Esophageal Chemoradiation: Dose, Technique, Response, and Salvage. Definitive chemoradiation requires a complete plan for patients with esophageal cancer who are not proceeding to surgery. In this episode, we work through patient selection, concurrent treatment, dose evidence, target definition, and normal-tissue protection, then connect toxicity management and response asses...

Episode 3: Resectable Esophageal and GEJ Cancer: CROSS, FLOT, and Perioperative Selection. The modern approach to resectable esophageal cancer has evolved beyond simply asking if a patient needs preoperative treatment; for most locally advanced cancers, the answer is yes. In this episode, we dive into the more complex decision-making process: determining which preoperative strategy such as the CRO...

Episode 2: Esophageal and GEJ Cancer Anatomy, Workup, Staging, and Surgery. In this episode, we explore how esophageal cancer punishes imprecise anatomy. We discuss why a difference of just a few centimeters can fundamentally alter the primary site, staging schema, regional nodal map, operative approach, and the necessity for specialized airway or peritoneal staging procedures.

This is Episode one: G I Oncology Foundations, Workup, Intent, Planning Safety, and Cross Cutting Toxicity. The most dangerous G I oncology error is often not choosing the wrong dose. It is answering the dose question before proving the diagnosis, stage, treatment intent, and problem that radiation is supposed to solve.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition. Episode 30 is the comprehensive Thoracic mock oral. Three case blocks cover metastatic disease with consolidation versus oligoprogression, superior vena cava syndrome and thymic carcinoma, and a post-treatment pulmonary syndrome followed by thoracic reirradiation decisions. Each case includes a contrasting twist that changes the reco...

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition. Episode 29 is a board-synthesis workshop built around the order of operations that keeps thoracic decisions safe. We move from diagnosis and stage uncertainty to management-changing workup, invasive staging, operability, resectability, treatment intent, multimodality sequence, radiation indication, planning priorities, toxicity, surv...

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition. Episode 28 approaches thoracic reirradiation as a new treatment decision made in the shadow of a prior course. Before discussing dose, we define intent, alternatives, expected benefit, prior-plan reconstruction, registration uncertainty, cumulative exposure, and the organ that could turn an elegant plan into a catastrophic event. The...

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition. Episode 27 tackles thoracic toxicity as a differential-diagnosis problem. Cough, dyspnea, dysphagia, fever, fatigue, chest discomfort, and palpitations may reflect radiation injury, infection, recurrent cancer, airway obstruction, cardiac disease, dehydration, systemic therapy, or more than one process at once. Using a post-chemoradi...

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition. Episode 26 treats pleural mesothelioma as the surface-spreading disease it is—not as a spherical lung mass. We cover diagnostic adequacy, histology, anatomic extent, operability, and whether meaningful cytoreduction is achievable before turning to the radiation problem. Planning then branches by operation. After lung-sparing pleurect...

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition. Episode 25 uses thymic malignancies to build a disciplined approach to rare thoracic tumors. We address diagnostic pathways, myasthenic symptoms, biopsy-route hazards, the difference between operability and an R0 resection, true invasion versus simple contact, postoperative radiation selection, and reconstruction of the tumor bed. Th...

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition. Episode 24 brings structure to thoracic palliation and oncologic emergencies. We balance the danger of moving too slowly during airway, vascular, spinal-cord, pericardial, or respiratory compromise against the harm of giving empiric radiation to a stable patient before preserving diagnosis, stage, and the best procedural or systemic...

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition. Episode 23 separates two often-confused strategies in limited metastatic non-small cell lung cancer: comprehensive treatment of every known site after systemic control and ablation of a resistant site during otherwise effective therapy. A lesion count alone is not a biological diagnosis or a treatment indication. Using a thoracic pri...

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition. Episode 22 focuses on integrating radiation and systemic therapy in metastatic non-small cell lung cancer without allowing two independent treatment calendars to collide. The durable skill is not memorizing one universal drug-hold table, but making a transparent risk decision for the exact agent, target, dose per fraction, organ expo...

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition. Episode 21 is a three-block mock oral covering fit unresectable stage III non-small cell lung cancer, frail unresectable stage III disease, and small cell lung cancer. The cases test concurrent versus modified chemoradiation, planning and toxicity management, post-treatment selection, brain-directed decisions, surveillance, and salva...

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition. Episode 20 clarifies the selective role of thoracic radiation in extensive-stage small cell lung cancer. We distinguish consolidative treatment after a favorable systemic response from palliative treatment for symptoms or threatened thoracic function—two indications that may use the same machine but differ in intent, urgency, target,...

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition. Episode 19 examines the decision between prophylactic cranial irradiation and structured MRI surveillance in small cell lung cancer, including the role of hippocampal avoidance. We place the evidence in its imaging and treatment era rather than treating older trials as if every patient had modern brain MRI and dependable salvage acce...

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition. Episode 18 follows limited-stage small cell lung cancer from the start of chemotherapy through thoracic radiation planning and post-treatment decisions. We discuss treatment timing, fractionation, target construction, the use of pre- and post-chemotherapy disease information, image guidance, and how toxicity or interruptions change t...

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition. Episode 17 establishes the foundations of small cell lung cancer care: pathologic confirmation, complete staging, mandatory attention to brain imaging, the rare role of surgery, and entry into curative treatment for limited-stage disease. We focus on the decisions that prevent stage and intent errors—distinguishing limited from exten...

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition. Episode 16 begins where definitive chemoradiation ends. We organize post-treatment care around three competing possibilities: eligibility for consolidation therapy, clinically important toxicity, and early relapse or progression. The episode shows how to interpret symptoms and imaging without prematurely labeling every pulmonary chan...

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition. Episode 15 is a planning-focused guide to definitive radiation for stage III non-small cell lung cancer. We move from simulation and motion assessment to gross disease, nodal volumes, target margins, technique, image guidance, adaptive triggers, and plan appraisal. The core challenge is not simply achieving coverage. It is building a...

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition. Episode 14 builds the definitive treatment framework for unresectable stage III non-small cell lung cancer. We begin by confirming a curable nonsurgical disease state, completing stage-defining workup, and deciding whether the patient can safely complete concurrent chemoradiation or needs a modified sequence. From there, we connect t...

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition. Episode 13 is a three-block mock oral in localized and resectable non-small cell lung cancer. The cases move from surgery versus stereotactic radiation for peripheral disease, to central and ultracentral anatomy, and then to resectable nodal and superior sulcus disease with multimodality sequencing and postoperative decisions. Pause...

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition. Episode 12 takes a selective, evidence-based approach to postoperative radiation therapy for non-small cell lung cancer. We reconstruct residual disease, margin status, nodal burden and geography, surgical quality, the preoperative disease map, competing systemic risk, cardiopulmonary reserve, and the target that would actually be tr...

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition. Episode 11 examines trimodality therapy through the demanding example of a superior sulcus tumor. Before chemotherapy and radiation begin, the team must define thoracic-inlet invasion, nodal status, the feasibility of a margin-negative operation, the patient’s ability to tolerate that operation, and what the definitive fallback will...